These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

536 related articles for article (PubMed ID: 21942977)

  • 1. Subcutaneous recombinant interferon-β-1a (Rebif®): a review of its use in the treatment of relapsing multiple sclerosis.
    Sanford M; Lyseng-Williamson KA
    Drugs; 2011 Oct; 71(14):1865-91. PubMed ID: 21942977
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparing the cost-effectiveness of disease-modifying drugs for the first-line treatment of relapsing-remitting multiple sclerosis.
    Goldberg LD; Edwards NC; Fincher C; Doan QV; Al-Sabbagh A; Meletiche DM
    J Manag Care Pharm; 2009 Sep; 15(7):543-55. PubMed ID: 19739877
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and tolerability of intramuscular interferon beta-1a compared with subcutaneous interferon beta-1a in relapsing MS: results from PROOF.
    Minagara A; Murray TJ;
    Curr Med Res Opin; 2008 Apr; 24(4):1049-55. PubMed ID: 18315940
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunomodulators and immunosuppressants for multiple sclerosis: a network meta-analysis.
    Filippini G; Del Giovane C; Vacchi L; D'Amico R; Di Pietrantonj C; Beecher D; Salanti G
    Cochrane Database Syst Rev; 2013 Jun; 2013(6):CD008933. PubMed ID: 23744561
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness of four immunomodulatory therapies for relapsing-remitting multiple sclerosis: a Markov model based on long-term clinical data.
    Bell C; Graham J; Earnshaw S; Oleen-Burkey M; Castelli-Haley J; Johnson K
    J Manag Care Pharm; 2007 Apr; 13(3):245-61. PubMed ID: 17407391
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Teriflunomide for multiple sclerosis.
    He D; Zhang C; Zhao X; Zhang Y; Dai Q; Li Y; Chu L
    Cochrane Database Syst Rev; 2016 Mar; 3(3):CD009882. PubMed ID: 27003123
    [TBL] [Abstract][Full Text] [Related]  

  • 7. What is new in the treatment of multiple sclerosis?
    Weinstock-Guttman B; Jacobs LD
    Drugs; 2000 Mar; 59(3):401-10. PubMed ID: 10776827
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative injection-site pain and tolerability of subcutaneous serum-free formulation of interferonβ-1a versus subcutaneous interferonβ-1b: results of the randomized, multicenter, Phase IIIb REFORMS study.
    Singer B; Bandari D; Cascione M; LaGanke C; Huddlestone J; Bennett R; Dangond F;
    BMC Neurol; 2012 Dec; 12():154. PubMed ID: 23216674
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alemtuzumab versus interferon beta 1a for relapsing-remitting multiple sclerosis.
    Zhang J; Shi S; Zhang Y; Luo J; Xiao Y; Meng L; Yang X
    Cochrane Database Syst Rev; 2017 Nov; 11(11):CD010968. PubMed ID: 29178444
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term subcutaneous interferon beta-1a therapy in patients with relapsing-remitting MS.
    Kappos L; Traboulsee A; Constantinescu C; Erälinna JP; Forrestal F; Jongen P; Pollard J; Sandberg-Wollheim M; Sindic C; Stubinski B; Uitdehaag B; Li D
    Neurology; 2006 Sep; 67(6):944-53. PubMed ID: 17000959
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improving compliance with interferon-beta therapy in patients with multiple sclerosis.
    Portaccio E; Amato MP
    CNS Drugs; 2009; 23(6):453-62. PubMed ID: 19480465
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of interferon beta-1a subcutaneously three times weekly on clinical and radiological measures and no evidence of disease activity status in patients with relapsing-remitting multiple sclerosis at year 1.
    Traboulsee A; Li DKB; Cascione M; Fang J; Dangond F; Miller A
    BMC Neurol; 2018 Sep; 18(1):143. PubMed ID: 30217172
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Spotlight on Interferon-beta-1b in relapsing-remitting and secondary progressive multiple sclerosis.
    McCormack PL; Scott LJ
    BioDrugs; 2004; 18(5):343-7. PubMed ID: 15377176
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interferon-beta-1b: a review of its use in relapsing-remitting and secondary progressive multiple sclerosis.
    McCormack PL; Scott LJ
    CNS Drugs; 2004; 18(8):521-46. PubMed ID: 15182221
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PRISMS: the story of a pivotal clinical trial series in multiple sclerosis.
    Cohen BA; Rivera VM
    Curr Med Res Opin; 2010 Apr; 26(4):827-38. PubMed ID: 20121658
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial.
    Mikol DD; Barkhof F; Chang P; Coyle PK; Jeffery DR; Schwid SR; Stubinski B; Uitdehaag B;
    Lancet Neurol; 2008 Oct; 7(10):903-14. PubMed ID: 18789766
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical and MRI efficacy of sc IFN β-1a tiw in patients with relapsing MS appearing to transition to secondary progressive MS: post hoc analyses of PRISMS and SPECTRIMS.
    Freedman MS; Brod S; Singer BA; Cohen BA; Hayward B; Dangond F; Coyle PK
    J Neurol; 2020 Jan; 267(1):64-75. PubMed ID: 31559532
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alemtuzumab for multiple sclerosis.
    Riera R; Porfírio GJ; Torloni MR
    Cochrane Database Syst Rev; 2016 Apr; 4(4):CD011203. PubMed ID: 27082500
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Full results of the Evidence of Interferon Dose-Response-European North American Comparative Efficacy (EVIDENCE) study: a multicenter, randomized, assessor-blinded comparison of low-dose weekly versus high-dose, high-frequency interferon beta-1a for relapsing multiple sclerosis.
    Schwid SR; Panitch HS
    Clin Ther; 2007 Sep; 29(9):2031-48. PubMed ID: 18035202
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomized, comparative study of interferon beta-1a treatment regimens in MS: The EVIDENCE Trial.
    Panitch H; Goodin DS; Francis G; Chang P; Coyle PK; O'Connor P; Monaghan E; Li D; Weinshenker B; ;
    Neurology; 2002 Nov; 59(10):1496-506. PubMed ID: 12451188
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.